Content Status
Type
Linked Node
Co-trimoxazole prophylactic therapy in persons with HIV and TB coinfection
Learning ObjectivesThe learner will be able to discuss objectives, indications, dosage, and duration of CPT and identify where it is dispended.
The objective of Co-trimoxazole Preventive Therapy (CPT) is to reduce morbidity and mortality among People Living with HIV (PLHIV) from opportunistic infections.
CPT is effective in preventing a range of bacterial fungal and protozoal opportunistic infections in PLHIV including Pneumocystis Pneumonia (PCP) caused by the fungus Pneumocystis jirovecii, toxoplasmosis, bacterial pneumonias, nocardiasis and isosporiasis. Hence, CPT is a standard component of HIV care.
Co-trimoxazole is a combination of two drugs – Sulfamethoxazole (SMX) and Trimethoprim (TMP). A single-strength tablet contains 400 mg SMX and 80 mg TMP
There are two types of CPT prophylaxis:
1. Primary prophylaxis - Aims to avoid the first occurrence of infection
2. Secondary prophylaxis - Aims to avoid the recurrence of infection after successful treatment
Prophylaxis |
Recommendations |
Commencing primary CPT |
Initiated in PLHIV with:
|
Commencing secondary CPT |
For all patients who have completed successful treatment for Pneumocystis pneumonia (PCP) |
Timing the initiation of Co- trimoxazole in relation to initiating ART |
|
Dosage of Co-trimoxazole in adults and adolescents |
One double-strength tablet (or two single-strength) tablets once daily – total daily dose of 960 mg (800 mg Sulfamethoxazole (SMX) + 160 mg Trimethoprim (TMP)) |
Co-trimoxazole for pregnant and breastfeeding women |
|
Patients allergic to sulpha- based medications |
|
Monitoring |
No specific laboratory monitoring is required in patients receiving co-cotrimoxazole the a |
Discontinuation of CPT (primary or secondary) |
When CD4 count > 350/mm3 on two different occasions 6 months apart with an ascending trend and devoid of any WHO clinical stage 3 and 4 conditions |
Group |
When to start Co-trimoxazole? |
When to discontinue CPT prophylaxis? |
Notes |
All HIV- exposed infants/ children |
From 6 weeks of age (or at first encounter with health services) |
HIV infection has been reliably excluded by a negative antibody test at 18 months, regardless of ARV initiation. |
In infants confirmed to be HIV infected, CPT should be continued till 5 years of age |
All HIV- infected infants and children up to 5 years |
Irrespective of WHO stage or CD4 counts or CD4% |
At 5 years of age, when clinical or immunological indicators confirm restoration of the immune system for more than 6 months i.e. in a child > 5 years of age with a WHO T- stage 1 or 2 and CD4 count of > 350 cell/mm3 on two occasions not less than 3 months apart |
Children with history of severe adverse reactions (grade 4 reaction) to co-trimoxazole or other sulpha drugs as well as children with glucose-6-phosphate dehydrogenase deficiency (G6PD) should not be initiated on CPT. The alternative drug, in this case, is Dapsone 2 mg/kg once daily (not to exceed 100 mg/day) orally. |
All HIV-infected |
WHO Stage 3 and 4 irrespective of CD4 |
When clinical or immunological indicators confirm restoration of the immune system for more than 6 months i.e. in a child > 5 years of age with a WHO T- stage 1 or 2 and CD4 count of > 350 cell/mm3 on two occasions not less than 3 months apart |
|
As secondary prophylaxis |
After completion of treatment for PCP |
< 5 years old: Do not stop |
|
Weight (kg) |
Approx. Age |
Cotrimoxazole once a day |
|||
Syrup 5ml (40 TMP/200 SMX) |
Child Tablet (20 TMP, 100 SMX) |
Single strength adult (80 TMP/ 400 SMX) |
Double strength adult tablet (160 TMP/800 SMX) |
||
<5 |
6 weeks – 2 months |
2.5 ml |
1 tablet |
- |
- |
5-10 |
2-12 months |
5 ml |
2 tablets |
½ tablet |
- |
10-15 |
1-2 years |
7.5 ml |
3 tablets |
½ tablet |
- |
15-22 |
2-5 years |
10 ml |
4 tablets |
1 tablet |
½ tablet |
>22 |
>5 years |
15 ml |
- |
1 ½ tablet |
½ to 1 tablet depending on weight |
Dispensation of CPT:
References
Assessment
Question |
Answer 1 |
Answer 2 |
Answer 3 |
Answer 4 |
Correct answer |
Explanation |
Page ID |
Part of pre-test |
Part of post-test |
Which of the following statements is true? |
A PLHIV diagnosed with PTB or EPTB should be given CPT. |
A CLHIV diagnosed with PTB or EPTB should be given CTP. |
An infant diagnosed with TB and is born to a mother with HIV should be given CPT. |
All the above |
4 |
All the statements are true. |
|
Yes |
Yes |
Page Tags
Content Creator
Reviewer
Target Audience
- Log in to post comments
Comments
Cotrimoxazole is a…
Mariyam Thu, 15/09/2022 - 14:47
Cotrimoxazole is a combination of two drugs – Sulfamethoxazole and Trimethoprim. It is effective in preventing a range of bacterial fungal and protozoal opportunistic infections in PLHIV including Pneumocystis pneumonia (PCP) caused by the fungus Pneumocystis jirovecii, Toxoplasmosis, Bacterial pneumonias, Nocardiasis and Isosporiasis.
Cotrimoxazole Preventive Therapy (CPT) aims to avoid either the first occurrence of these infections (primary prophylaxis) or their recurrence (secondary prophylaxis)
PLHIV/CLHIV with Pulmonary TB classifies as WHO clinical stage 3 and PLHIV with Extra-Pulmonary TB classifies as WHO clinical stage 4
Co-trimoxazole Preventive Therapy (CPT) for Adults and Adolescents living with HIV:
Prophylaxis
Recommendations
Commencing primary CPT
Co-trimoxazole Prophylaxis must be initiated in PLHIV with:
PLHIV with Pulmonary TB classifies as WHO clinical stage 3
PLHIV with Extra-Pulmonary TB classifies as WHO clinical stage 4
Commencing secondary CPT
For all patients who have completed successful treatment for PCP
Timing the initiation of Co- trimoxazole in relation to initiating ART
Dosage of Co-trimoxazole in adults and adolescents
One double-strength tablet (or two single-strength) tablets once daily– total daily dose of 960 mg (800 mg SMZ + 160 mg TMP)
Co-trimoxazole for pregnant and breastfeeding women
Patients allergic to sulpha- based medications
Monitoring
No specific laboratory monitoring is required in patients receiving co- trimoxazole
Discontinuation of co- trimoxazole prophylaxis (primary or secondary)
When CD4 count > 350/mm3 on two different occasions 6 months apart with an ascending trend and devoid of any WHO clinical stage 3 and 4 conditions
Cotrimoxazole Preventive therapy in Infants/Children exposed to/living with HIV:
Unlike adults CPT is indicated for infants exposed to HIV who are uninfected (HIV Exposed Infant/Child = Infant/Child born to HIV infected woman, is reliably excluded or confirmed with HIV status and is no longer exposed to HIV through breast feeding)
Group
When to start Cotrimoxazole?
When to discontinue CPT?
All HIV- exposed infants/ children
From 6 weeks of age (or at first encounter with health services)
HIV infection has been reliably excluded by a negative antibody test at 18 months, regardless of ARV initiation
All HIV- infected infants and children up to 5 year of age
Irrespective of WHO stage or CD4 counts or CD4%
At 5 years of age, when clinical or immunological indicators confirm restoration of the immune system for more than 6 months i.e. in a child > 5 years of age with a WHO T
- stage 1 or 2 and CD4 count of > 350 cell/mm3 on two occasions not less than 3 months apart
All HIV-infected
children > 5 years of age
WHO Stage 3 and 4 irrespective of CD4
OR
CD4 < 350 cells/mm3 irrespective of WHO staging
When clinical or immunological indicators confirm restoration of the immune system for more than 6 months i.e. in a child > 5 years of age with a WHO T- stage 1 or
2 and CD4 count of > 350 cell/mm3 on two occasions not less than 3 months apart
Secondary prophylaxis
After completion of treatment for PCP
— < 5 years old: do not stop
— > 5 years old: may consider stopping as per the adult guidelines
Slides can be broken down…
Dr. Priyadarshini Thu, 28/12/2023 - 23:30
Slides can be broken down further